Stockhub

IVERIC bio, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 September 2022

  • curprev 16:1816:18, 23 September 2022 95.149.241.133 talk 1,930 bytes +1,930 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-r..."
Retrieved from "https://stockhub.co/research/IVERIC_bio,_Inc."